Market Cap 1.99B
Revenue (ttm) 2.20B
Net Income (ttm) -713.41M
EPS (ttm) N/A
PE Ratio 29.61
Forward PE 4.88
Profit Margin -32.45%
Debt to Equity Ratio 0.56
Volume 2,961,400
Avg Vol 3,436,400
Day's Range N/A - N/A
Shares Out 105.58M
Stochastic %K 15%
Beta 0.21
Analysts Sell
Price Target $21.88

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
Thaigrlsrk
Thaigrlsrk Jul. 14 at 11:54 PM
$SRPT Hey Kim – we are in a quiet period for earnings. Happy to discuss after we report. Thanks! – Ian Ian Estepan President & COO e: [email protected] p: 1-617-460-9771 Executive Assistant: Nancy Scarfo p: 1-857-253-8826 e: [email protected] Sarepta Therapeutics 215 First Street, 4th flr Cambridge, MA 02142
1 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Jul. 14 at 11:39 PM
0 · Reply
Thaigrlsrk
Thaigrlsrk Jul. 14 at 10:03 PM
$SRPT $SRPT So i asked a couple pointed questions about the progress in the Sirolimus trial and was told he would be happy to discuss it after the earnings call they are in a quiet period. I may not need to ask after the call.
3 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Jul. 14 at 9:26 PM
$SRPT This was posted on X and I saw a few people were talking about it on Yahoo Message Board. Not sure if legit or not...
1 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Jul. 14 at 9:13 PM
$SRPT Hope everyone had a nice day
0 · Reply
Czar_of_Losses
Czar_of_Losses Jul. 14 at 8:43 PM
$SRPT How does one really determine trendlines/resistance with stocks like this? When something is so range bound for a year how do you accurately determine when to buy/sell? I feel like the standard playbook doesn't apply for biotech but after this stock I'll never touch biotechs again man a year of nothing ahhaa
1 · Reply
7990E
7990E Jul. 14 at 8:29 PM
$SRPT Keeping the price down has not been for free the last 6 months, shorts had to increase their positions 50% (10 million shares) sure very easy to do it, but to cover those 30 million shares without spiking the share price is going to be fun, unless they have an evil plan and institutional holders decide to sell 30% percent of all the shares or even 100% shares to get out. We’ll see for sure! Outcome will depend on who is running the show and if they are on the same side of the fda.
1 · Reply
KY3000
KY3000 Jul. 14 at 8:18 PM
$SRPT fuking retail like usual, WS are POS
0 · Reply
Pipipopopipi
Pipipopopipi Jul. 14 at 8:01 PM
$SRPT let’s hear a big round of applause to the Douggie the mf on another milestone. 17 again and on route to 0. Bravo
1 · Reply
Pipipopopipi
Pipipopopipi Jul. 14 at 6:58 PM
$SRPT rumour is douggie the crook he is going around smiling around the office. He is shouting i’m back you bunch of goofies
1 · Reply
Latest News on SRPT
Sarepta Therapeutics Transcript: AGM 2026

Jun 4, 2026, 10:00 AM EDT - 5 weeks ago

Sarepta Therapeutics Transcript: AGM 2026


Sarepta price target lowered to $19 from $20 at Evercore ISI

2026-05-15T12:30:23.000Z - 2 months ago

Sarepta price target lowered to $19 from $20 at Evercore ISI


Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year

2026-05-07T00:41:58.000Z - 2 months ago

Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year


Sarepta Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics Earnings Call Transcript: Q1 2026


Sarepta Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics Quarterly report: Q1 2026


Sarepta Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics Earnings release: Q1 2026


Sarepta Therapeutics Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics Slides: Q1 2026


Sarepta Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Sarepta Therapeutics Proxy statement: Proxy filing


Roche decision could hurt Sarepta in U.S., says H.C. Wainwright

2026-04-16T16:20:19.000Z - 3 months ago

Roche decision could hurt Sarepta in U.S., says H.C. Wainwright


Sarepta price target raised to $19 from $18 at RBC Capital

2026-04-07T15:08:48.000Z - 3 months ago

Sarepta price target raised to $19 from $18 at RBC Capital


Deutsche ups Sarepta target, says 35% stock rally overdone

2026-03-26T12:40:44.000Z - 3 months ago

Deutsche ups Sarepta target, says 35% stock rally overdone


Sarepta price target raised to $35 from $29 at Wedbush

2026-03-26T12:37:02.000Z - 3 months ago

Sarepta price target raised to $35 from $29 at Wedbush


Sarepta price target raised to $13 from $9 at Citi

2026-03-26T09:56:24.000Z - 3 months ago

Sarepta price target raised to $13 from $9 at Citi


Sarepta Therapeutics Transcript: Study result

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics Transcript: Study result


Sarepta Therapeutics Press release: Study result

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics Press release: Study result


Sarepta Therapeutics Slides: Study result

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics Slides: Study result


Sarepta Therapeutics CEO Ingram to retire by year end

Feb 26, 2026, 5:05 AM EST - 4 months ago

Sarepta Therapeutics CEO Ingram to retire by year end


Sarepta Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Earnings Call Transcript: Q4 2025


Sarepta Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Annual report: Q4 2025


Sarepta Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Earnings release: Q4 2025


Sarepta Therapeutics Slides: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Slides: Q4 2025


Sarepta Therapeutics Transcript: Study result

Jan 26, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics Transcript: Study result


Sarepta Therapeutics Press release: Study result

Jan 26, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics Press release: Study result


Sarepta Therapeutics Slides: Study result

Jan 26, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics Slides: Study result


Sarepta Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Sarepta Therapeutics Earnings Call Transcript: Q3 2025


Sarepta Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Sarepta Therapeutics Quarterly report: Q3 2025


Sarepta Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Sarepta Therapeutics Earnings release: Q3 2025


Sarepta Therapeutics Slides: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Sarepta Therapeutics Slides: Q3 2025


Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:24 PM EST - 9 months ago

Sarepta's Duchenne gene therapy misses main goal in study


Thaigrlsrk
Thaigrlsrk Jul. 14 at 11:54 PM
$SRPT Hey Kim – we are in a quiet period for earnings. Happy to discuss after we report. Thanks! – Ian Ian Estepan President & COO e: [email protected] p: 1-617-460-9771 Executive Assistant: Nancy Scarfo p: 1-857-253-8826 e: [email protected] Sarepta Therapeutics 215 First Street, 4th flr Cambridge, MA 02142
1 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Jul. 14 at 11:39 PM
0 · Reply
Thaigrlsrk
Thaigrlsrk Jul. 14 at 10:03 PM
$SRPT $SRPT So i asked a couple pointed questions about the progress in the Sirolimus trial and was told he would be happy to discuss it after the earnings call they are in a quiet period. I may not need to ask after the call.
3 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Jul. 14 at 9:26 PM
$SRPT This was posted on X and I saw a few people were talking about it on Yahoo Message Board. Not sure if legit or not...
1 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Jul. 14 at 9:13 PM
$SRPT Hope everyone had a nice day
0 · Reply
Czar_of_Losses
Czar_of_Losses Jul. 14 at 8:43 PM
$SRPT How does one really determine trendlines/resistance with stocks like this? When something is so range bound for a year how do you accurately determine when to buy/sell? I feel like the standard playbook doesn't apply for biotech but after this stock I'll never touch biotechs again man a year of nothing ahhaa
1 · Reply
7990E
7990E Jul. 14 at 8:29 PM
$SRPT Keeping the price down has not been for free the last 6 months, shorts had to increase their positions 50% (10 million shares) sure very easy to do it, but to cover those 30 million shares without spiking the share price is going to be fun, unless they have an evil plan and institutional holders decide to sell 30% percent of all the shares or even 100% shares to get out. We’ll see for sure! Outcome will depend on who is running the show and if they are on the same side of the fda.
1 · Reply
KY3000
KY3000 Jul. 14 at 8:18 PM
$SRPT fuking retail like usual, WS are POS
0 · Reply
Pipipopopipi
Pipipopopipi Jul. 14 at 8:01 PM
$SRPT let’s hear a big round of applause to the Douggie the mf on another milestone. 17 again and on route to 0. Bravo
1 · Reply
Pipipopopipi
Pipipopopipi Jul. 14 at 6:58 PM
$SRPT rumour is douggie the crook he is going around smiling around the office. He is shouting i’m back you bunch of goofies
1 · Reply
Pipipopopipi
Pipipopopipi Jul. 14 at 6:15 PM
$SRPT would not be surprised if after all crook douggie gets to the end of the year and announces he’s staying after all. Came to the conclusion that his passion it’s money
0 · Reply
jm0olah
jm0olah Jul. 14 at 6:08 PM
$SRPT every day since jun 26 same volume basically. Just painting the price however they want lol
2 · Reply
Gekkosneighbor
Gekkosneighbor Jul. 14 at 4:22 PM
$SRPT You buy in the $15-$16 range and you trim as it goes north of $20. Waiting for the magical re-rate has been a fools game. I kick myself every time I deviate from this strategy.
2 · Reply
Initiator1
Initiator1 Jul. 14 at 3:53 PM
$SRPT Back to 18,000 shares. A fraction of my previous position. I likely won’t add more. The stock has been a huge opportunity cost for me. Good luck to all longs
3 · Reply
DeportedGreta
DeportedGreta Jul. 14 at 3:46 PM
$SRPT doug is a pos
0 · Reply
Pipipopopipi
Pipipopopipi Jul. 14 at 3:45 PM
$SRPT hey Douggy the crook i guess family isn’t that important after all. Moneyvtalks isn’t it ? What an …..
0 · Reply
fpak
fpak Jul. 14 at 3:19 PM
$SRPT There goes the "uptrend". Down we go again.
1 · Reply
BiodegradableBurger
BiodegradableBurger Jul. 14 at 3:18 PM
$SRPT weekdays prime time Shit show channel is back.
0 · Reply
Ceedj
Ceedj Jul. 14 at 3:13 PM
$SRPT stock has been in the dumps for well over a year. NO WAY someone needs to sell this aggressively.
1 · Reply
KY3000
KY3000 Jul. 14 at 2:48 PM
$SRPT take it to 5, this is useless
0 · Reply
Pipipopopipi
Pipipopopipi Jul. 14 at 2:14 PM
$SRPT like i said yesterday mg doug was on holidays but he got an emergency call from his shorts buddies so he went back to work to make sure the stock crashes again and his buddies are happy. Nothing new
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Jul. 14 at 2:10 PM
$SRPT bears are OK, but bears masqueraded as bulls with a ~21/sh PT gives me a brain freeze. If folks believe this sh1t its done for a while.
0 · Reply